REDWOOD CITY, Calif.--(BUSINESS WIRE)--C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s esophagus or BE), today announced that two studies reinforcing the clinical efficacy and safety of its Coldplay CryoBalloon® Focal Ablation System were presented at United European Gastroenterology Week, held in Barcelona from October 24-28.
The first study was an oral presentation of an ongoing multicenter prospective trial evaluating the efficacy and performance of the Coldplay CryoBalloon in treating patients with flat, dysplastic BE. A total of 37 ablations were performed in 26 patients with a median cryoablation procedure time of 5 (IQR 2-6) minutes. Follow-up endoscopy with biopsy was performed in 24 of 26 patients with no strictures detected. Complete eradication of BE islands was observed in 35/37 (95%) of treated areas. In two patients, residual BE was observed during follow-up. Of these, one patient received incomplete ablation at the time of the procedure and another experienced residual BE (50% of original size) after initial, endoscopically complete ablation of the island. No adverse events occurred during ablation. Seven patients (27%) reported mild pain directly after the procedure and two patients reported mild pain during swallowing at two days post-procedure.
“Radiofrequency ablation (RFA), the current gold standard treatment for eradicating Barrett’s esophagus, has several limitations including the requirements for cumbersome control units and multiple deployment steps,” said Bas Weusten, M.D., Ph.D., Professor of Innovative Gastrointestinal Endoscopy, St. Antonius Hospital Gastroenterology & Hepatology, The Netherlands, and presenting study author. “These data demonstrate that treatment of Barrett’s esophagus using C2 Therapeutics’ CryoBalloon Focal Ablation System is an attractive and effective solution enabling a short and convenient 10-second treatment time.”
A second study presented at the conference evaluated the feasibility of endoscopic eradication of early esophageal squamous cell neoplasia (ESCN) with the Coldplay CryoBalloon Focal Ablation System.
About Barrett’s Esophagus
Barrett’s Esophagus develops as a result of chronic injury from gastroesophageal reflux disease (GERD). Over time, the normal esophageal lining is replaced with abnormal cells (Barrett’s Esophagus), putting patients at greater risk of developing cancer of the esophagus.
About C2 Therapeutics
C2 Therapeutics was founded in 2007 to address the limitations of current Barrett’s esophagus treatment options. Headquartered in Redwood City, California, C2 is a privately held company whose Coldplay CryoBalloon® Ablation Systems set a new standard for simplicity in the endoscopic ablation of Barrett’s Esophagus. The technology comprises a through-the-scope, highly compliant balloon catheter that is simultaneously inflated and cooled by an inert cryogen delivered through a small disposable handheld unit. Operation is intuitive, fast and cost-effective. The Coldplay CryoBalloon® Focal Ablation System eliminates the need for precise sizing, multiple deployment steps, and large controller units.
For more information on C2 Therapeutics and its products, please visit www.c2therapeutics.com.